Phong Phu Pharmaceutical JSC (HNX:PPP)
Vietnam · Delayed Price · Currency is VND 20,000
-100 (-0.50%)
At close: Nov 3, 2026
HNX:PPP Ratios and Metrics
Market cap in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 176,000 | 180,400 | 155,760 | 130,240 | 113,520 | 154,880 | |
Market Cap Growth | 3.09% | 15.82% | 19.60% | 14.73% | -26.71% | 55.75% |
Enterprise Value | 117,178 | 148,925 | 127,715 | 102,957 | 98,639 | 155,753 |
Last Close Price | 20000.00 | 19000.00 | 15116.54 | 11845.69 | 9333.44 | 11880.29 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 4.83 | 10.89 | 10.02 | 7.18 | 5.51 | 9.17 |
PS Ratio | 1.05 | 1.29 | 1.13 | 0.86 | 0.75 | 1.16 |
PB Ratio | 1.14 | 1.30 | 1.15 | 1.00 | 0.91 | 1.33 |
P/TBV Ratio | 1.27 | 1.47 | 1.31 | 1.15 | 1.07 | 1.59 |
P/FCF Ratio | 5.24 | 11.81 | 9.28 | 7.47 | 5.64 | 8.54 |
P/OCF Ratio | 4.92 | 10.74 | 8.99 | 5.91 | 5.42 | 8.03 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.70 | 1.07 | 0.93 | 0.68 | 0.66 | 1.17 |
EV/EBITDA Ratio | 2.74 | 5.88 | 5.22 | 3.69 | 3.14 | 6.02 |
EV/EBIT Ratio | 3.05 | 7.03 | 6.31 | 4.46 | 3.92 | 7.91 |
EV/FCF Ratio | 3.49 | 9.75 | 7.61 | 5.91 | 4.90 | 8.59 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.05 | - | - | - | 0.02 |
Debt / EBITDA Ratio | 0.21 | 0.25 | - | - | - | 0.08 |
Debt / FCF Ratio | 0.27 | 0.41 | - | - | - | 0.11 |
Net Debt / Equity Ratio | -0.38 | -0.31 | -0.29 | -0.25 | -0.21 | -0.14 |
Net Debt / EBITDA Ratio | -1.37 | -1.71 | -1.63 | -1.15 | -0.84 | -0.62 |
Net Debt / FCF Ratio | -1.75 | -2.84 | -2.38 | -1.84 | -1.31 | -0.89 |
Asset Turnover | 0.91 | 0.81 | 0.84 | 0.96 | 0.96 | 0.89 |
Inventory Turnover | 2.27 | 2.35 | 2.65 | 3.00 | 2.54 | 2.31 |
Quick Ratio | 1.57 | 1.54 | 1.64 | 1.57 | 1.21 | 0.74 |
Current Ratio | 2.57 | 2.66 | 2.89 | 2.71 | 2.35 | 1.80 |
Return on Equity (ROE) | 26.31% | 13.54% | 13.06% | 15.77% | 17.09% | 15.07% |
Return on Assets (ROA) | 13.05% | 7.71% | 7.74% | 9.08% | 10.02% | 8.19% |
Return on Invested Capital (ROIC) | 32.00% | 17.78% | 16.65% | 19.22% | 20.25% | 16.28% |
Return on Capital Employed (ROCE) | 24.90% | 15.30% | 14.90% | 17.70% | 20.20% | 16.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 2, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 20.71% | 10.29% | 11.14% | 15.43% | 18.16% | 10.91% |
FCF Yield | 19.09% | 8.47% | 10.78% | 13.38% | 17.72% | 11.71% |
Dividend Yield | 7.50% | - | 8.48% | 7.23% | 10.85% | - |
Payout Ratio | 35.09% | 71.28% | 60.16% | 62.02% | 50.08% | 35.37% |
Buyback Yield / Dilution | 2.62% | - | - | 9.83% | 0.34% | 0.72% |
Total Shareholder Return | 10.12% | - | 8.48% | 17.06% | 11.20% | 0.72% |